Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Sponsor
Beijing Sanbo Brain Hospital
Study ID
NCT04070040
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Primary Central Nervous System Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.

Study Details

This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.

Key Dates

Start date
Feb 13, 2020
Status verified
Oct 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab
    Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.

Primary Outcome Measure

ORR(objective response rate) [ Time Frame: Up to three years ]

Related Studies